>BackgroundWithdrawal of conditional regulatory approval or subsidization of new medicines when subsequent evidence does not confirm early trial results may not'/> Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Southern Med Review >Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study
【24h】

Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study

机译：收益不确定的药品的监管撤回：贝伐单抗案例研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

id="__sec1" class="sec sec-first">>BackgroundWithdrawal of conditional regulatory approval or subsidization of new medicines when subsequent evidence does not confirm early trial results may not be well understood or accepted by the public.
机译：id =“ __ sec1” class =“ sec sec-first”> >背景在后续证据不能确认早期试验结果的情况下，有条件的监管批准或对新药的补贴可能不会被很好地理解或接受由公众。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号